Mark Rus, MSc., Chief Executive Officer and Director of Delix Therapeutics.
Clinical interest in psychedelic chemicalsclassic hallucinogens like LSD (D-lysergic acid diethylamide) and dissociative drugs like ketamineis becoming increasingly mainstream. In 2019, the U.S. Food and Drug Administration (FDA) approved a nasal spray called esketamine (Spravato) containing a ketamine-like compound for treatment-resistant depression.
Although ketamine and now esketamine are available in clinics, most psychedelic compounds remain illegal. Psilocybin, the magic ingredient in psychedelic mushrooms, is farthest down the path to FDA approval. Just a few weeks ago, researchers at NYU Grossman School of Medicine showed that two doses of psilocybin, a compound found in psychedelic mushrooms, reduce heavy drinking by 83 percent on average among heavy drinkers when combined with psychotherapy.
Besides the issue of legality, taking psychedelic compounds has risks. In addition to poisoning, there are long-term side effects that include memory loss, seizures, and anxiety. Also, the eponymous side effects of psychedelic compoundshallucinations (seeing the world turn into fractals, hearing voices, or tasting colors) and dissolution (feeling out of control or disconnected from their body and environment)pose a risk to serious harm because of the profound alteration of perception and mood. While not inherently dangerous, consumption of psychedelics has led people to harm themselves and others while having a mind-altering experience, with tales of people becoming suicidal and violent.
To harness the clinical power of psychedelics, the mechanism of action underlying the antidepressant and anxiolytic effects need to be separated from hallucinatory and dissolutive. Research has shown that result from their ability to promote structural and functional plasticity in prefrontal cortical neurons. Isolating the chemical structures driving the rapid and long-lasting antidepressant and anxiolytic effects of psychedelics may be used as lead structures to identify next-generation neurotherapeutics with improved efficacy and safety profiles.
Delix Therapeutics is a neuroscience company focused on harnessing the power of isolating psychoplastogensnovel neuroplasticity-promoting therapeuticsto better treat mental health disorders at scale. Based in Boston, Massachusetts, the companys compounds, which do cause not cause hallucinatory or dissociative side effects, are easily manufactured small molecules capable of rapidly inducing structural and functional neural changes in targeted brain areas. Many of these molecules are inspired by psychedelic compounds and preserve their efficacy-promoting mechanisms while avoiding their hallucinogenic properties and other safety liabilities.
GEN Edge has taken a look into the motivation and structure of Delixs R&D pipeline with CEO Mark Rus, a veteran industry executive. He joined Atlas Venture after previously leading Shire Pharmaceuticals Global Neuroscience Business.
GEN Edge: What motivated the founding of Delix Therapeutics?
Rus: Neuropsychiatry and neurodegeneration have had a shortage of innovation for the past few decades. Were still using a similar selective serotonin reuptake inhibitor (SSRI). You cant even find meaningful advances on the neurodegenerative side. Pick your access moral, strategic, or financial. All roads lead to the need for better mental health treatments. The treatments do not match the unmet need in the space.
Through that motivation, Delix co-founder David Olson was working on ketamine at the Broad Institute on why these rapid structural and functional changes, called neuroplasticity, occur in the PFC. We know the intangible benefits associated with like ketamine or true psychedelics like psilocybin. Perceived dissolution of ego and the unique intrinsic experiences that one can have are very powerful. Who am I to say that those cant be the most transformative experiences for someone in their lives?
But Im a neuro drug developer, and Im more interested to know whats happening at the synapse or circuit-based level. It was inconceivable to me that structural and functional neuroplasticity did not play a role. That ultimately led to the foundation of Delix.
GEN Edge: How do psychoplastogens work?
Rus: If you think of a neuron as a trees trunk, the dendrite is the branch coming off that tree and the synapses or the leaves on the edge of the branches. A well-functioning circuit connective circuit of pre-frontal cortex (PFC) to other brain parts is like a rich forest, where the neurons are all connected. But then, in a scenario where theres trauma, whether genetic or external, in both cases, those leaves start falling off, the dendrite branches retract, and the synaptic connectivity in the circuit is essentially lost or suboptimal.
To me, thats a fascinating nexus that sits at the heart of a range of neuropsychiatric and neurodegenerative conditions. So, why do psychedelics seem to help so quickly and so robustly? Its an indisputable fact that there is a massive and significant growth in the dendritic spine density process called synaptogenesis. David and I felt it was worth pursuing and drawing that lineup further. There are great companies, people, and funding behind hallucinatory-based approaches. But what if you could do it without the hallucinatory-based approach and some other aspects that may be suboptimal for some of these compoundsside effects, like HERG inhibition, other than removing the hallucinations?
For any brand, product, or therapeutic, I ask: What does it mean to a patient? Is it going to help? Will it make a difference in motivating them to want to take it? What does it mean for a payer and the prescriber? Is it sufficiently simple or motivating enough to change an ingrained habit that physicians may have in treating a particular condition? What does it mean for pharmacists, psychologists, and others in terms of ease of use? What does it mean for policymakers?
What motivated the Delix story was whether we could pursue the neuroplasticity-focused element, tease that out, and subtly tweak known hallucinatory compounds to generate our own novel IP. These eventually become very different compounds that, inspired by the hallucinatory ones, become more tolerable and orally bioavailable. You can take them home and thus be scalable to fit the current care frameworks and speak to the scalability of manufacturing, commercial, and patient access.
GEN Edge: What advantages do psychoplastogens have over hallucinogenic psychedelics?
Rus: I saw an inherent scalability issue regarding first- or second-generation hallucinatory psychedelics. Its not a reason not to do it. People can and will be helped by those experiences, but spending eight hours in an inpatient treatment clinic with multiple therapists surrounding you to support you and to walk you through that mission is one of the reasons why Spravatowhich a lot of people were excited by, the first ketamine derivative that was approved launched by Janssen and justifiably created a lot of motivation for our space and approved by the FDAhasnt been a huge success. Its tough to get high throughput payers to pay for it, and people that want to come back to take it with that high degree of complexity. Now, many people have been and will be helped with it.
There is a wide proportion of patients with comorbidities who will never even be candidates for hallucinatory psychedelic therapy. For someone with bipolar, schizophrenia, or a history of psychosis, its not the first, second, or third thing youd want to take to risk exacerbating that condition. When you start moving in that neurodegenerative direction and particularly individuals who are perhaps older or later in life, the ability to build rapport with therapists is plausible for some, and for others, it isnt. Im not sure how one discerns that early on.
So, the need for more options is there. Theres a mix of scalability, comorbidity, and other related reasons. That makes a lot of sense for more treatments in our approach. And thats what the Delix approach was all about. We wanted to take this non-hallucinatory approach to validate it preclinically. Ive been searching for the right scalable approach in this space because I see the promise that rapid structural and functional neuroplasticity changes may bring.
Delix is a psychoplastogen platform company. We now have thousands of compounds at this stage at various stages of characterization. We have two candidates that we nominated last year and moved into IND-enabling studies. We are in the process of completing those now. Well be in phase one early next year to show the translatability of this non-hallucinatory reality in man, efficacy, and safety with our approach while continuing to characterize, develop, and nominate subsequent candidates. We have a pipeline that we can produce from our platform as we drive forward the Structure-Activity Relationships (SAR) and the related screening discovery full of the scheme.
GEN Edge: What is the Delix R&D pipeline scheme?
Rus: Were certainly inspired by the fact that this work has been going on for a long time. Were standing on the shoulders of a lot of great work that has been going on for decades in the hallucinatory psychedelic space. But all our novel chemical and composition matter-supported compounds are synthesized and built in-house and are inspired by predicate compounds.
We have a phenotypic-driven drug discovery engine. Each one of these lens tests produces compounds that fit the Delix narrative for what an eventual clinical candidate would be. The first thing we do is assess for psychoplastogenic propertiesif something is a compound generating robust neurite outgrowth. We look at targeted binding and functional assays that one would typically use and the classic battery of safety profiles you do in neuro-drug discovery, such as ADME and PK. Then, we quickly test for the likelihood of hallucinogenic properties and an efficacy profile. So, weve got a range of multiple assays we assess so that as early as possible in the process, we can take some compounds off the assembly line that we feel are likely to display hallucinogenic properties and separate them from the non-hallucinogenic ones.
We dont allocate resources, time, or effort to the early-stage compounds weve developed and synthesized that have robust IP but are likely to be hallucinogenic. Over time, I feel those could be good candidates for other companies who are better natural owners and stewards of the hallucinatory approach. Thats not our lane, but we have identified and can build compounds that perhaps have an optimized hallucinatory profile.
The preclinical to clinical translatability is not great for hallucinatory properties. Some pretty good models like head twitch and related rodent models also have a pretty good R-square value for not being hallucinatory in man. We test efficacy through assays such as the non-forced four swim test, where we do the highest possible bar and most possible assays to demonstrate effectiveness in early-stage rodent models.
We also directly compare the compounds that we find most attractive against positive and negative controls. How are they doing against ketamine for being rapid-acting and long-lasting? We also dont want to develop another SSRI or something you must take daily. We want to be a once a month, twice a month, once every two months therapy, not once a day. Finally, we look at safety, toxicology, and dosing models that inform eventual clinical candidate selection and then patient subtypes.
GEN Edge: What is Delixs approach to funding?
Rus: The syndicate you build is essential, not just from the capital perspective. Its important to build with investors who truly understand neuro-drug development and are interested in building a leading neuroscience company, not short-term investors. And were fortunate to have that syndicate, having raised about a hundred million last year through our Series A and convertible note round. We have great teammates from ARTIS Ventures, RA Capital Management, founding investor OMX Ventures, and others.
GEN Edge: Whats on the horizon for Delix?
Rus: We want to get into the clinic to demonstrate human translatability for a Delix compound ASAP next year and continue to advance our pipeline candidates out of our platform, ready to move into IND-enabling studies adjacent to those clinical studies from phase one. We feel that being the leading non-hallucinatory, psychoplastogen company globally is a step towards being a leading neuroscience company by 2030.
Were building out our headquarters, and well be moving in next year here in Massachusetts in Q1. We couldnt be more thrilled to have a shot at making a big meaningful difference in something that all of us face one way or the othereither with ourselves, loved ones, or friendswith the suboptimal standard of care in mental health.
See the original post here:
- Review: Tripping on Utopia Complicates the History of Psychedelics - AOL - March 16th, 2024 [March 16th, 2024]
- Psychedelics Are Going Mainstream. Investing in Them Hasn't. - The Wall Street Journal - January 7th, 2024 [January 7th, 2024]
- Another Study Shows African Psychedelic Plant Ibogaine Treats Traumatic Brain Injury in Vets With 'Dramatic' Results - Good News Network - January 7th, 2024 [January 7th, 2024]
- Massachusetts Lawmakers Will Be Forced To Consider Psychedelics Legalization Measure That Activists Petitioned ... - Marijuana Moment - January 5th, 2024 [January 5th, 2024]
- VA to begin researching psychedelics as treatment option for veterans - Government Executive - January 5th, 2024 [January 5th, 2024]
- VA Is Funding New Research On Psychedelics' Benefits For Veterans With PTSD And Depression - Marijuana Moment - January 5th, 2024 [January 5th, 2024]
- VA ramps up study of psychedelic to treat PTSD - The American Legion - January 5th, 2024 [January 5th, 2024]
- Scientists predict DMT trip from cardiac activity - Big Think - January 5th, 2024 [January 5th, 2024]
- If psychedelics heal, how do they do it? | Proceedings of the National Academy of Sciences - pnas.org - January 5th, 2024 [January 5th, 2024]
- Psychedelics for acquired brain injury: a review of molecular mechanisms and therapeutic potential | Molecular ... - Nature.com - January 5th, 2024 [January 5th, 2024]
- U.S. Rep. Correa supports using psychedelics to treat veterans with PTSD - New Santa Ana - January 5th, 2024 [January 5th, 2024]
- DEA Confirms That Psychedelic Mushroom Spores Are Federally Legal Prior To Germination - Marijuana Moment - January 5th, 2024 [January 5th, 2024]
- Psychedelics for Psych Conditions Made Their Mark in 2023 - Medpage Today - January 5th, 2024 [January 5th, 2024]
- 2023: A Good Trip Around the Sun for Psychedelics - The National Law Review - January 5th, 2024 [January 5th, 2024]
- Understanding the Role of the FDA in Advancing Psychedelic Therapy - Medriva - January 5th, 2024 [January 5th, 2024]
- MAPS PBC Closes $100m Series A, Rebrands to Lykos Therapeutics - Psychedelic Alpha - January 5th, 2024 [January 5th, 2024]
- Closing the innovation gap: Advancing psychedelic therapy and medicines in EU mental health care - Open Access Government - January 5th, 2024 [January 5th, 2024]
- The Austin Chronic: SXSW Is High on Psychedelics, as Cannabis Programming Wanes - Austin Chronicle - January 5th, 2024 [January 5th, 2024]
- This Forgotten Psychedelic Could Revolutionize Traumatic Brain Injury Treatment - Inverse - January 5th, 2024 [January 5th, 2024]
- A 'milestone' for psychedelics: Pentagon directed to study alternative treatments for veterans - Washington Times - January 5th, 2024 [January 5th, 2024]
- Psychedelic Drugs Are Rushing Towards Approval for Therapy. Here's What's Next - Singularity Hub - January 5th, 2024 [January 5th, 2024]
- The top 8 psychedelic books you need to read | GreenState - GreenState - January 5th, 2024 [January 5th, 2024]
- Lykos Therapeutics Secures $100M in Series A Funding, Rebrands from MAPS PBC - Green Market Report - January 5th, 2024 [January 5th, 2024]
- DEA Calls For Even More THC, Psilocybin And DMT To Be Produced For Research In 2024 - Marijuana Moment - January 5th, 2024 [January 5th, 2024]
- Here's What You Missed in Cannabis, Psychedelics This Week - TipRanks.com - TipRanks - January 5th, 2024 [January 5th, 2024]
- You're not tripping: State and local leaders give psychedelics another chance - Route Fifty - December 22nd, 2023 [December 22nd, 2023]
- Are Consciousness-Expanding Psychedelics Like Psilocybin More Effective Than Prozac, Zoloft, Xanax, and Other ... - Nautilus - December 22nd, 2023 [December 22nd, 2023]
- RFK, Ramaswamy And Williamson Push Psychedelics Reform On Presidential Campaign Trail - Marijuana Moment - December 22nd, 2023 [December 22nd, 2023]
- Peyote is the darling of the psychedelics renaissance. Indigenous users say it co-opts a sacred way of life - The Guardian US - December 22nd, 2023 [December 22nd, 2023]
- USask researchers explore untold history of psychedelics - News - University of Saskatchewan - USask News - December 22nd, 2023 [December 22nd, 2023]
- California Governor Says Psychedelics Have 'Profound' Healing Potential, But He's Undecided On Legalization Bill As ... - Marijuana Moment - September 25th, 2023 [September 25th, 2023]
- As psychedelic-assisted therapy grows, so does interest from a new group: chaplains - NPR - September 25th, 2023 [September 25th, 2023]
- This Maine City Moves Unanimously On Decriminalizing Psychedelics: Focus On Public Health - Benzinga - September 25th, 2023 [September 25th, 2023]
- Tech Leaders Are Finding Balance Through Microdosing Psychedelics - The Dales Report - September 25th, 2023 [September 25th, 2023]
- Chronic Pain Can Be Treated by Psychedelics, Survey Suggests - Psychedelic Spotlight - September 25th, 2023 [September 25th, 2023]
- Insights Into the First Psychedelic-Assisted Therapy Guidelines With ... - Psychedelic Spotlight - September 25th, 2023 [September 25th, 2023]
- Living with long-term cancer is depressing. Texas doctors say psychedelics could help - The Hill - July 19th, 2023 [July 19th, 2023]
- Couples Are Doing MDMA and Ketamine Therapy To Save Their Relationships - VICE - July 19th, 2023 [July 19th, 2023]
- The Way People Are Using Psychedelics Is Changing Amid Reform ... - Marijuana Moment - July 19th, 2023 [July 19th, 2023]
- [WATCH] Turn on, tune in, legalise: Could psychedelics be next in ... - MaltaToday - July 19th, 2023 [July 19th, 2023]
- Will Psychedelics Be Rescheduled After FDA Approval? - Harris Bricken - July 19th, 2023 [July 19th, 2023]
- The Psychedelic Preparedness Scale: A Tool to Optimize Trip ... - Filter - July 19th, 2023 [July 19th, 2023]
- How to Test Psychedelics for Adulterants with Testing Kits - Psychedelic Spotlight - July 19th, 2023 [July 19th, 2023]
- Cannabis Science Conference to debut in Providence, R.I., with ... - GlobeNewswire - July 19th, 2023 [July 19th, 2023]
- New Speaker Rivas weighs in on psychedelics, housing and health care worker minimum wage - Yahoo News - July 19th, 2023 [July 19th, 2023]
- TDR's Top 5 Psychedelic Developments For The Week Of July 10 - The Dales Report - July 19th, 2023 [July 19th, 2023]
- Psychedelic Treatment with Psilocybin Relieves Major Depression, Study ... - February 20th, 2023 [February 20th, 2023]
- Johns Hopkins Launches Center For Psychedelic Research - February 20th, 2023 [February 20th, 2023]
- Psilocybin Treatment for Major Depression Effective for Up to a Year ... - February 20th, 2023 [February 20th, 2023]
- Inside the Johns Hopkins Psilocybin Playlist - Hopkins Medicine - February 20th, 2023 [February 20th, 2023]
- Research Story Tip: Psychedelic Drug Psilocybin Tamps Down Brains Ego ... - February 20th, 2023 [February 20th, 2023]
- Psychedelics: Risks, benefits, and more - Medical News Today - February 18th, 2023 [February 18th, 2023]
- Psychedelic Drug Effects, Side Effects & Dangers - January 25th, 2023 [January 25th, 2023]
- Psychedelics Decriminalization Project In Berkeley, Cal Includes ... - January 6th, 2023 [January 6th, 2023]
- Ancient mummified child was drugged with psychedelics before ritual ... - December 14th, 2022 [December 14th, 2022]
- The therapeutic potential of psychedelics - Science - December 14th, 2022 [December 14th, 2022]
- Changing Lives with Psychedelics: How Connecticut researchers are using magic mushrooms to help people overcome depression, OCD - WTNH.com - November 19th, 2022 [November 19th, 2022]
- Penis Envy Mushroom | Legal Psychedelics | Magic Mushroom - November 7th, 2022 [November 7th, 2022]
- Psychedelics. Discussing natural and synthetic friends. Science, News ... - November 5th, 2022 [November 5th, 2022]
- The Harms of Psychedelics Need to Be Put Into Context - WIRED - November 5th, 2022 [November 5th, 2022]
- Packers' Aaron Rodgers says psychedelics led to his back-to-back MVP ... - October 28th, 2022 [October 28th, 2022]
- With Promise of Legalization, Psychedelic Companies Joust Over Future Profits - The New York Times - October 25th, 2022 [October 25th, 2022]
- How do psychedelics work? This brain region may explain their effects - PBS - October 21st, 2022 [October 21st, 2022]
- Why is the American right suddenly so interested in psychedelic drugs? - The Guardian - October 19th, 2022 [October 19th, 2022]
- Can Psychedelics Cure? Science Is on the Verge of Finding Out - Newsweek - October 19th, 2022 [October 19th, 2022]
- Large national survey suggests that the use of psychedelics is not associated with lifetime cancer development - PsyPost - October 19th, 2022 [October 19th, 2022]
- This Pharma Company Just Scored Another Psychedelics Patent And Set Its Sights On 70 More - Small Pharma - Benzinga - October 19th, 2022 [October 19th, 2022]
- What Made the Mushrooms Magic: Psychedelic Study Explores the Odd Evolution of Mind-Altering Fungi - The Debrief - October 19th, 2022 [October 19th, 2022]
- Psychedelics And Wellness: The Healing Company Buys PepsiCo-Backed Superfoods Company - (HLCO) - Benzinga - October 19th, 2022 [October 19th, 2022]
- What's on the Colorado ballot? Housing, psychedelics, school meals, alcohol, taxes and more | FOX31 Denver - FOX 31 Denver - October 19th, 2022 [October 19th, 2022]
- DoseConnect to Sponsor the Tech Stage at Wonderland Miami by Microdose - Benzinga - October 19th, 2022 [October 19th, 2022]
- What Is Going on With Bright Minds (DRUG) Stock Today? - InvestorPlace - October 19th, 2022 [October 19th, 2022]
- Psychedelics May Ease Fear of Death and Dying - October 17th, 2022 [October 17th, 2022]
- TDR's Top 5 Psychedelic Developments For The Week Of October 10 - The Dales Report - October 17th, 2022 [October 17th, 2022]
- DEA Wants To Boost Production Of Cannabis & Psychedelics For Research In 2023 - Benzinga - October 17th, 2022 [October 17th, 2022]
- Talk set to explore psychedelics and mental health - Reading Today - October 17th, 2022 [October 17th, 2022]
- Silo Wellness Closes Acquisition of Dyscovry Science and Its Psilocybin Pharmaceutical Biosynthesis and Research Portfolio - Yahoo Finance - October 17th, 2022 [October 17th, 2022]
- How does psilocybin rewire the brain? - Open Access Government - October 17th, 2022 [October 17th, 2022]
- HYTN Awarded Controlled Drugs and Substances Dealers License Allowing for Production and Sale of Psilocybin - Yahoo Finance - October 17th, 2022 [October 17th, 2022]
- The Healing Company acquires leading superfoods business, Your Super, and lands $150M credit facility to expand community of brands - Yahoo Finance - October 17th, 2022 [October 17th, 2022]